150
Participants
Start Date
June 27, 2019
Primary Completion Date
March 8, 2022
Study Completion Date
March 8, 2022
Edoxaban
Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
Presidio Ospedaliero SS. Antonio e Biagio, Alessandria
Istituto Tumori di Bari, Bari
Azienda Ospedalier Spedali Civili di Brescia, Brescia
Ospedale S.Giacomo, Castelfranco Veneto
ARNAS Garibaldi, Catania
Istituti Ospitalieri di Cremona, Cremona
Ospedale di Faenza, Faenza
Ospedale Civile di Guastalla, Guastalla
Ospedale Mater Salutis, Legnago
Istituto Nazionale dei Tumori di Milano, Milan
Ospedali Monaldi Cotugno, Napoli
Istituto Oncologico Veneto - IRCCS, Padua
Azienda Ospedaliero-Universitaria di Parma, Parma
AUSL/IRCCS di Reggio Emilia, Reggio Emilia
Ospedale degli Infermi, Rimini
ASST Valleolona, PO Saronno, Saronno
Ospedale Mauriziano, Torino
Ospedale Molinette, Torino
Gruppo Oncologico Italiano di Ricerca Clinica
OTHER